This company is no longer active
Diffusion Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Diffusion Pharmaceuticals's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 11% annually.
Key information
-2.2%
Earnings growth rate
72.5%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -91.9% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Diffusion Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -13 | 10 | 4 |
31 Mar 23 | 0 | -15 | 10 | 6 |
31 Dec 22 | 0 | -16 | 9 | 7 |
30 Sep 22 | 0 | -15 | 8 | 7 |
30 Jun 22 | 0 | -24 | 8 | 8 |
31 Mar 22 | 0 | -24 | 8 | 8 |
31 Dec 21 | 0 | -24 | 7 | 8 |
30 Sep 21 | 0 | -25 | 7 | 10 |
30 Jun 21 | 0 | -17 | 7 | 11 |
31 Mar 21 | 0 | -18 | 7 | 11 |
31 Dec 20 | 0 | -16 | 6 | 9 |
30 Sep 20 | 0 | -16 | 6 | 9 |
30 Jun 20 | 0 | -14 | 5 | 7 |
31 Mar 20 | 0 | -12 | 5 | 6 |
31 Dec 19 | 0 | -12 | 5 | 7 |
30 Sep 19 | 0 | -14 | 5 | 6 |
30 Jun 19 | 0 | -18 | 5 | 6 |
31 Mar 19 | 0 | -18 | 6 | 6 |
31 Dec 18 | 0 | -27 | 6 | 6 |
30 Sep 18 | 0 | -20 | 6 | 6 |
30 Jun 18 | 0 | -10 | 6 | 6 |
31 Mar 18 | 0 | 4 | 6 | 6 |
31 Dec 17 | 0 | -3 | 6 | 5 |
30 Sep 17 | 0 | -7 | 6 | 5 |
30 Jun 17 | 0 | -15 | 8 | 5 |
31 Mar 17 | 0 | -30 | 6 | 5 |
31 Dec 16 | 0 | -18 | 9 | 6 |
30 Sep 16 | 0 | -18 | 9 | 6 |
30 Jun 16 | 0 | -14 | 5 | 6 |
31 Mar 16 | 0 | -12 | 6 | 5 |
31 Dec 15 | 0 | -7 | 3 | 4 |
Quality Earnings: DP80 is currently unprofitable.
Growing Profit Margin: DP80 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DP80 is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare DP80's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DP80 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: DP80 has a negative Return on Equity (-91.92%), as it is currently unprofitable.